Australia markets closed

Neuren Pharmaceuticals Limited (NEU.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
20.68-0.10 (-0.48%)
At close: 04:10PM AEST

Neuren Pharmaceuticals Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
61 3 9092 0480

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.CEO, MD & Executive Director1.07MN/AN/A
Ms. Lauren Frazer C.A.CFO & Company SecretaryN/AN/AN/A
Mr. Lawrence Glass BA (Biology)Chief Science OfficerN/AN/AN/A
Mr. Gerry ZhaoVice President of Corporate DevelopmentN/AN/AN/A
Dr. Liza A. Squires M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Corporate governance

Neuren Pharmaceuticals Limited’s ISS governance QualityScore as of 1 July 2024 is 5. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.